The world’s first use of the Blu Build Cesium-131 brachytherapy delivery system to treat prostate cancer at Hollings Cancer Center is an important development for prostate cancer patients and their doctors. Here’s the WTAT-TV report.
Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial Results
Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year RICHLAND, WASHINGTON – September 17, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...
